







CQUIN Differentiated MCH Workshop

May 25-27, 2021

Morkor Newman Owiredu (WHO)

Framing Integration of Family Planning in Postpartum care

[May 2021]



Background: Postnatal and Postpartum Care

- "Post natal" period the period from after birth up to 6 weeks (42 days).
- Standard four postnatal visits provide opportunity to provide care:
 - First day (24 hours):
 - Day 3 (48–72 hours):
 - Between days 7-14 and
 - At six weeks
- Services are provided for both mother and child by a 'skilled attendant/health worker'
- WHO guidelines address the **timing and content** of essential and routine postnatal care for mothers and newborns to:
 - end preventable death, improve health outcomes, strengthen community-based health systems, address gender and equity issues, and emphasize respectful and womencentred maternity care
- Extended "postpartum" includes the period up to 12 months after birth https://apps.who.int/iris/bitstream/10665/93680/1/9789241506496 eng.pdf)

Why is postpartum family planning important?

- Opportunity for prevention of unintended pregnancy and closely spaced pregnancies through the first 12 months following childbirth
- Based on WHO recommendation of an interval of 24 months or more before attempting a next pregnancy after a live birth, to reduce the risks of adverse outcomes for mother and child
- The seven components of postpartum care include one for addressing 'Sexuality, contraception, and birth spacing'



Postpartum Family Planning

• Should not be considered a 'vertical' programme, but rather as an **integrated part of existing** maternal and child health and family planning efforts.

• Requires holistic and evidence-based programme strategies that contribute to **strengthened health systems** and **sustained improvements** in high-quality services that put **people at the centre of health care**.

Women and adolescent girls living with HIV post partum

- Among those with greatest unmet need for contraception: do not get needed services to support longer birth intervals or reduce unintended pregnancy
- Important because rapid repeat pregnancy affect maternal health and increases risk of adverse maternal and neonatal outcomes
- Require counseling about
 - the risk of pregnancy from the early postpartum especially when not fully breastfeeding /adhering to lactational amenorrhea method criteria
 - Healthy pregnancy spacing (based on reproductive intentions)
 - Choice of a safe and effective method
- Should also have been discussed during the ANC period



Leveraging DSD for HIV treatment to strengthen family planning care





Provides important opportunity to

- Engage women and girls living with HIV
- 2. Utilize DSD referral and follow up as opportunities for continuity of family planning care
- Promote use of long-acting reversible contraceptives among clients in DSD models for ART
- 4. Align contraceptive and ART resupplies in DSD models
- 5. Integrate family planning and ART care in facilities and communities




Information and guidance draw upon existing guidelines



| Antigen | | Age of 1st Dose | Doses in Primary Series | Interval Between Doses | | | Booster Dose | Considerations |
|--|-------------------------|--|-------------------------------|--|--|----------------------------|---------------------------------------|---|
| | | | | 1st to 2sd | 2 nd to 3 nd | 3⁴ to 4° | Booster Dose | (see footnotes for details) |
| Recommendation | ons for all ch | | | | | | | |
| BCG 1 | | As soon as possible after birth | 1 | | | | | Exceptions HIV |
| Hepatitis B ² | Option 1 | As soon as possible after birth (<24h) | 3 | 4 weeks (min) with DTP1 | 4 seeks (min) with DTP3 | | | Premature and low birth weight Co-administration and combination vaccine High risk groups |
| | Option 2 | As soon as possible after birth (<24h) | 4 | 4 weeks (min) with DTP1 | 4 weeks (min) with DTP2 | 4 weeks (min),with DTP3 | | |
| Polio ³ | OPV | 6 weeks (see footnote for birth dose) | 3 | 4 weeks (min) with DTP2 | 4 weeks (min) with DTP3 | | | OPV birth dose Transmission and importation risk criteria IPV booster needed for early schedul |
| | IPV / OPV Sequential | 8 weeks (IPV 1**) | 1-2 IPV 2 OPV | 4-8 weeks | 4-8 weeks | 4-8 weeks | | |
| | IPV | 8 weeks | 3 | 4-8 weeks | 4:8 weeks | | (see footnote) | |
| DTP + | | 6 weeks (min) | 3 | 4 weeks (min) - 8 weeks | 4 weeks (min) - 8 weeks | | 1-6 years of age (see footnote) | Delayed/ Interrupted schedule Combination vaccine |
| Haemophilus influenzae type b * | | 6 weeks (min) with DTP1, 24 months (max) | 3 | 4 weeks (min) with DTP2 | 4 weeks (min) with DTP3 | | (see footnote) | Single dose if >12 months of age Delayed/ interrupted schedule Co-administration and combination vectine |
| Pneumococcal (Conjugate) ⁶ | Option 1 Option 2 | 6 weeks (min) 6 weeks (min) | 3 2 | 4 weeks (min) 8 weeks (min) | 4 weeks | | (see footnote) 9-15 months | Vaccine options Initiate before 6 months of age Co-administration HIV+ and preterm neonates booste |
| Rotavirus ⁷ | Rotarix Rota Teq | 6 weeks (min) with DTP1 6 weeks (min) with DTP1 | 2 | 4 weeks (min) with DTP2 4 weeks (min) - 10 weeks with DTP2 | 4 weeks (min) with DTP3 | | | Vaccine options Not recommended if > 24 months of |
| Measles * | | 9 or 12 months (6 months min, see footnote) | 2 | 4 weeks (min) (see footnote) | | | | Combination vaccine: HEV early vaccination: Pregnancy |
| Rubella ° | | 9 or 12 months with measles containing vaccine | 1 | | | | | Achieve and sustain 80% coverage Combination vaccine and Co- administration: Pregnancy |
| HPV № | | Quadrivalent 9-13 years of age Bivalent 10-13 years of age | 3 | Quadrivalent - 2 mas (min 4 wks) Bivalent - 1 mas (max 2.5 mas) | Quadrivalent - 4 mos (min 12 wks) Bivelent : 5 mos | | | Vaccination of males for prevention of cervical cancer not recommende currently |













Reference materials

- Providing contraceptive services in the context of HIV treatment programmes. Implementation tool (English and French) https://apps.who.int/iris/bitstream/handle/10-665/325859/WHO-CDS-HIV-19.19-eng.pdf?ua=1
- Programming strategies for postpartum family planning. Geneva: World Health Organization; 2013 https://www.who.int/reproductivehealth/publications/family_planning/ppfp_strategies/en

